Retinalamin is a polypeptide bioregulator preparation derived from retinal tissue, classified as a Khavinson-class agent investigated for neuroprotective and anti-aging effects in photoreceptors and retinal ganglion cells, proposed to support visual function by modulating gene expression and cellular homeostasis in aging retinal tissue. Like other Khavinson bioregulator preparations, retinalamin is proposed to exert tissue-specific regulatory effects through intracellular transport of ultrashort active peptide components via amino acid carrier mechanisms, modulating transcriptional activity in retinal pigment epithelium and photoreceptor cells under degenerative or age-related stress conditions.

retinal cell protection, visual function restoration, macular degeneration support, anti-aging (eyes).

Research on Retinalamin primarily documents effects related to retinal cell protection and visual function restoration and macular degeneration support and anti-aging (eyes). These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

Reported contraindications and considerations for Retinalamin include bovine protein allergy. This is educational information only — consult a qualified healthcare professional before use.

For Retinalamin, its FDA status is not evaluated by the FDA, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

1 provider in the directory currently offers Retinalamin.

This review documents the cellular uptake mechanisms of short regulatory peptides including retinalamin via POT and LAT transporter systems, demonstrating nuclear translocation and chromatin binding activity relevant to retinalamin's transcriptional regulatory function in retinal tissue cells.